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Abstract 
 
Irradiation, or chemoradiotherapy, is curative treatment for oropharyngeal squamous cell 
carcinoma (OPSCC). Its invasiveness, however, can often overwhelm its efficacy. It is 
therefore urgent issue to develop methods to predict which patients would benefit from 
irradiation. Promoter DNA hypermethylation was recently reported to correlate with 
favorable OPSCC prognosis. It is still unclear, however, whether there is association 
between promoter DNA methylation and response to irradiation. In this study, we 
analyzed DNA methylation in the specimens from 40 OPSCC patients who had 
undergone irradiation, using the Infinium assay. Our results showed significant 
correlation between high levels of promoter DNA methylation and better response to 
treatment (P < 0.01). We used the 10 most differentially-methylated genes between 
responders and non-responders to develop a panel of predictive markers for efficacy. Our 
panel had high sensitivity, specificity, and accuracy (92%, 93%, 93%, respectively). We 
conducted pyrosequencing to quantitatively validate the methylation levels of 8 of the 10 
marker genes (ROBO1, ULK4P3, MYOD1, LBX1, CACNA1A, IRX4, DPYSL3, and 
ELAVL2) obtained by Infinium. The validation by pyrosequencing showed that these 8 
genes had a high prediction performance for the training set of 40 specimens and for a 
validation set of 35 OPSCC specimens, showing 96% sensitivity, 89% specificity, and 
94% accuracy. Methylation of these markers correlated significantly with better 
progression-free and overall survival rates, regardless of human papillomavirus status. 
These results indicate that increased DNA methylation is associated with better responses 
to irradiation therapy and that DNA methylation can help establish efficacy prediction 
markers in OPSCC. 
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Abbreviations: AUC, area under the curve; CI, confidence interval; CR, complete 
remission; DNMT, DNA methyl transferase; FFPE, formalin-fixed paraffin-embedded; 
GO, gene ontology; HNSCC, head and neck squamous cell carcinoma; HPV, human 
papillomavirus; lncRNA, long non-coding RNA; OPSCC, oropharyngeal squamous cell 
carcinoma; OS, overall survival; PFS, progression-free survival; ROC, receiver operating 
characteristic; SD, standard deviation; TCGA, The Cancer Genome Atlas; TSS, 
transcription start site 
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Introduction 
 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
cancer worldwide. Human papillomavirus (HPV) infection is a risk factor for HNSCC, 
especially for oropharyngeal squamous cell carcinoma (OPSCC). The increase in HPV 
infections in the past years has led to a significant escalation in HNSCC cases1-3. 
Irradiation, or chemoradiotherapy, is a potential treatment for HNSCC4, 5, but its 
invasiveness often leads patients to stop treatment, causing a severe decline in quality of 
life6, 7. Therefore, the optimization of irradiation therapy is an urgent issue. 
Ang et al. reported significantly better prognosis of HPV-positive than HPV-
negative OPSCC patients, but they also suggested the prevalence of a different prognostic 
factor8. Completed clinical trials have evaluated the therapeutic de-escalation of OPSCC 
therapy, but they are yet to obtain promising results9, 10. These trials stratified OPSCC 
patients into two groups according to HPV status, but did not consider any other 
molecular factors, which may be expected to affect mortality or irradiation efficacy11, 12. 
Therefore, an appropriate stratification of OPSCC patients and the development of 
classifier markers based on molecular biology could help personalize OPSCC treatment. 
Foy et al. predicted the efficacy of radiation therapy using the 13-gene expression-
based radioresistant score13. They established the efficacy prediction score through in 
vitro experiments and information extracted from The Cancer Genome Atlas (TCGA) 
database but did not validate the predictive performance using clinical samples. Li et al. 
successfully extracted candidate genes to predict the efficacy of radiotherapy using a 
comprehensive expression analysis of long non-coding RNA (lncRNA)14. The prediction 
performance of these genes, however, has not been verified. Although there have been 
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attempts to predict therapeutic efficacy using approaches based on molecular biology, the 
stratification of OPSCC patients using molecular markers aimed at therapeutic de-
escalation has not been established. 
Promoter DNA methylation is a critical epigenetic mechanism for regulation of 
gene expression15-18. We previously conducted a comprehensive DNA methylation 
analysis using Infinium 450K and revealed differential methylation levels in HNSCC 
cases. In that report, we also showed a significant association between DNA methylation 
of gene promoters, e.g. RXRG, and better prognosis in HNSCC19. Shen et al. proposed a 
prognosis prediction algorithm based on methylome and transcriptome data from clinical 
specimens of oral squamous cell carcinoma20. These suggest that aberrant DNA 
methylation could help predict HNSCC prognosis or the efficacy of the therapies against 
this disease. 
In this study, we thus analyzed promoter DNA methylation genome-widely in 
samples of OPSCC patients who had undergone irradiation using Infinium BeadArray. 
We established a panel of methylation marker genes to predict the efficacy of irradiation 
therapy with high accuracy. The panel was further validated using independent samples 
and pyrosequencing analysis to confirm the impact of DNA methylation on progression-
free survival (PFS) after irradiation and overall survival (OS).  
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Materials and Methods  
Full information is provided in the Supporting Materials and Methods. 
 
Clinical samples 
In this study, we analyzed 75 clinical OPSCC specimens (40 for the training set and 
35 for the validation set). 
For the training sample set, we enrolled 57 untreated OPSCC patients who visited 
Chiba University Hospital and would receive irradiation therapy. A total of 17 patients 
were excluded from this study because they were transferred to other hospitals, had 
undergone radical surgery before irradiation therapy, interrupted treatment due to adverse 
events, or withdrew before treatment. The specimens of the remaining 40 patients formed 
the training set (Fig. 1A). For the validation set, we enrolled 35 OPSCC patients who 
received irradiation therapy as first-line treatment at Chiba University Hospital or 
Hamamatsu University Hospital. The enrolled patients were all Asian.  
We collected the following clinicopathological factors for all the patients enrolled 
in this study: age, gender, tumor site, HPV-L1 status, clinical stage (T, N, stage based on 
UICC 8th edition21, 22), Brinkman index of 200 as smoking behavior23, 24, irradiation dose, 
and combination chemotherapy (Table S1). The 40 specimens of the training set were 
collected during biopsies performed before treatment, immediately frozen in liquid 
nitrogen, and stored at −80°C. Regarding the 35 validation samples, 24 were frozen 
specimens, and 11 were formalin-fixed paraffin-embedded (FFPE) specimens. 
All the participants were classified into responders and non-responders. We defined 
responders as patients who reached complete remission (CR) status and maintained it for 
> 6 months after irradiation therapy, or those for whom we did not find viable cancer cells 
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in the specimen collected during rescue surgery after irradiation. We defined non-
responders as patients who did not reach CR, those who had viable cancer cells in the 
specimen collected during rescue surgery after irradiation, or those who temporarily 
achieved CR but relapsed locally or by distant metastasis within six months after 
irradiation (Fig. 1C). 
Two independent pathologists microscopically examined the tumor cell content on 
the frozen or FFPE clinical specimens (Table S2). The specimens were dissected to enrich 
the tumor cells when necessary. We used 75 samples with > 50% of tumor cell content 
for subsequent molecular analyses. DNA was extracted using a QIA quick DNA mini-kit 
(Qiagen, Hilden, Germany) for frozen material and QIAamp DNA FFPE Tissue Kit 
(Qiagen) for FFPE material. The institutional review boards at Chiba University and 
Hamamatsu University approved the study protocol. 
 
Amplification of L1 DNA region in high-risk HPV 
We evaluated HPV infection by amplifying a portion of the L1 region of high-risk 
HPV including HPV 16, 18, 31, and 33 in the 40 training and 35 validation samples, using 
GP5 and GP6 primers as previously reported25. Positive PCR amplification was 
designated as HPV-L1(+). 
 
Infinium assay 
The Infinium assay of the training sample set were previously performed and the 
data were registered at GEO [accession number GSE124633]. The Infinium 
HumanMethylation450 BeadChip (Illumina) contains approximately 485,577 individual 
CpG sites. The β-value, ranging from 0.00 to 1.00, was measured by a methylated probe 
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relative to the sum of the methylated and unmethylated probes. The CpG score for each 
probe was calculated based on previous reports26, 27. Before analyzing the Infinium data, 
we extracted the upstream probe nearest to the transcription start site (TSS) of each gene 
(excluding sex chromosome genes) (n = 15,212) among 485,577 probes designed on the 
human genome. Among 15,212 probes, 10,048 (66%) were located in CpG islands and 
2,852 (19%) in CpG island shores, according to annotation by Illumina. Probes showing 
standard deviation (SD) > 0.11 among the training samples (n = 2,112) were extracted 
and used for the unsupervised two-way hierarchical clustering analysis. 
 
Gene Ontology (GO) analysis 
The GO enrichment analysis was conducted based on GO terms (biological process, 
cellular component, and molecular function) using the Gene Annotation and Analysis 
Resource at Metascape (http://metascape.org/gp/index.html#/main/step1). 
 
Pyrosequencing analysis 
The quantitative validation of methylation level in the 40 training and 35 validation 
samples was performed by pyrosequencing using the PyroMark Q96 (Qiagen) as 
previously reported27. Bisulfite conversion was performed using the Zymo EZ DNA 
Methylation Kit (Zymo Research, Irvine, CA) and 500 ng of genomic DNA for each 
sample. We amplified the promoter region covering the interested Infinium probe site and 
several surrounding CpG sites using bisulfite-treated DNA as a template. The 
amplification primers were designed by Pyro Q-CpG Software (Qiagen) and are shown 
in Supporting Information (Table S3). We calculated the average methylation value of the 
analyzed CpG sites as the representative methylation level of the gene. We prepared 
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methylation control samples (0%, 25%, 50%, 75%, and 100%) as described previously28, 
29, and analyzed them to confirm the quantification quality of the pyrosequencing assays 
(Fig. S1). 
 
Statistical analysis 
The association between clinicopathological factors and HPV-L1 status or DNA 
methylation was analyzed using Fisher’s exact test, χ2 test, and Student’s t-test. 
Unsupervised two-way hierarchical clustering was performed using Cluster 3.0 using the 
C Clustering Library version 1.59 software. We conducted the receiver operating 
characteristic (ROC) analysis in the training and validation sample sets to calculate the 
area under the curve (AUC) value. Progression-free survival (PFS) was measured from 
the completion date of irradiation therapy until the date of any relapse (local, locoregional, 
or distant metastasis) or death. OS was measured from the date of biopsy until the date of 
death. We estimated the PFS and OS distribution by the Kaplan-Meier method, and the 
difference between groups was determined by a log-rank test using R software (www.r-
project.org/). The univariate and multivariate analyses were performed using the Cox 
proportional hazard model for PFS. P < 0.05 was considered statistically significant. 
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Results 
 
Patient characteristics 
HPV status, clinical stage, and combination chemotherapy were significantly 
different between the responder and non-responder groups in all 75 samples of the 
training and validation sets. HPV infection was significantly more frequent in the 
responder group (73%) than the non-responder group (35%, P = 0.003). Lymph node 
metastasis was significantly less common in the responder group (67%) than the non-
responder group (91%, P = 0.04). Significantly fewer patients in the responder group 
(12%) had clinical Stage IVA than in the non-responder group (48%, P = 0.002). Age and 
gender were not significantly associated with irradiation response. Smokers were 
frequently observed in both groups; 81% in the responder group and 74% in the non-
responder group (P ≥ 0.5). 
 
DNA methylation and GO analyses 
The unsupervised two-way hierarchical clustering analysis of the 40 training 
samples classified them into two clusters: High- and Low-methylation groups. Responder 
samples were significantly enriched in the High-methylation group than the Low-
methylation group (23/27 vs. 6/13, P = 0.02). 
The two-way hierarchical clustering divided the 2,112 genes into three clusters (Fig. 
2). (i) A cluster of genes hypermethylated (mean β-value > 0.2) in both the High- and 
Low-methylation groups. This cluster included 722 genes, which showed considerably 
higher methylation levels in the High-methylation group (Fig. 2). The Infinium probes 
representing these genes were significantly enriched in either CpG islands or CpG island 
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shores (651 of 722, 90%, P = 1 × 10-4). GO terms such as “neuron fate commitment,” 
“brain development,” and “diencephalon development” were enriched in this cluster. (ii) 
A cluster of genes hypermethylated in the High-methylation group, but not in the Low-
methylation group. This cluster included 756 genes, and the Infinium probes representing 
these genes were significantly enriched in either CpG islands or CpG island shores (694 
of 756, 92%, P = 2 × 10-7). They showed significant enrichment of GO terms such as cell 
“morphogenesis,” “neuron differentiation,” and “renal system development.” (iii) A 
cluster of genes showing very high methylation levels in the High- and Low-methylation 
groups. This cluster included 634 genes, which did not show considerably higher 
methylation levels in the High-methylation group. The Infinium probes representing these 
genes were less frequently located in either CpG islands or CpG island shores (446 of 
634, 70%, P = 2 × 10-16). GO terms such as “cell adhesion,” “regulation of appetite,” and 
“gene silencing by RNA,” were significantly enriched in this cluster.  
 
Extraction of prediction markers for irradiation response 
Since the hierarchical clustering revealed a significant correlation between 
promoter DNA methylation and irradiation efficacy, we tried to extract prediction markers 
of therapeutic efficacy by comparing the methylation status of each gene in the responder 
and non-responder groups. A total of 92 genes had a significantly different methylation 
status in the two groups (P < 0.01). Overall, 87 of the 92 genes (95%) showed 
significantly higher methylation levels in the responder group. Residual 5 genes (5%) 
showed higher methylation levels in the non-responder group, presumably regarded as 
noise in the genome-wide analysis (Fig. 3A). GO terms such as “cell adhesion” and 
“regulation of cell proliferation” were significantly enriched in the 87 genes with higher 
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methylation levels in the responder group. Genes associated with these GO terms 
included ROBO1, FOXA2, LBX1, and SHISA6 (Fig. 3A). We extracted the 10 genes 
(ROBO1, FOXA2, ULK4P3, MYOD1, LBX1, CACNA1A, SHISA6, IRX4, DPYSL3, 
ELAVL2) with the most significant P-values between the responder and non-responder 
groups to serve as our candidate prediction markers of therapeutic efficacy (Fig. 3A, B). 
All the Infinium probes representing these 10 marker genes were located within either 
CpG islands or CpG island shores, and at 0 - 200 base pairs upstream from TSS.  
Among the 40 samples of the training set, 25 showed hypermethylation (β-value > 
0.2) in at least one of the 10 candidate marker genes, and which significantly correlated 
with responder cases (24/25 vs. 2/15, P = 7 × 10-7). To assess the efficacy prediction 
performance of the 10 markers for the training samples, we performed ROC analysis 
using the irradiation efficacy as an objective variable and the minimum β-value of the 10 
genes in each sample as an explanatory variable. The AUC value was 0.96, and the 
sensitivity, specificity, and accuracy were 92%, 93%, and 93%, respectively, with a β-
value threshold of 0.28 maximizing the accuracy of the efficacy prediction. 
 
Validation of promoter DNA methylation status by pyrosequencing 
In order to quantitatively verify the methylation status observed by the Infinium 
analysis, we conducted a pyrosequencing analysis for the candidate markers using the 40 
training samples. Pyrosequencing primers were successfully generated for 8 genes 
(ROBO1, ULK4P3, MYOD1, LBX1, CACNA1A, IRX4, DPYSL3, and ELAVL2), for which 
methylation control samples were quantified with a correlation coefficient R2 > 0.98 (Fig. 
S1). We could not generate appropriate primers for the remaining two genes. To confirm 
prediction performance using these 8 successful markers only, ROC analysis was 
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performed using Infinium data of these genes. The AUC value reached 0.97, and the 
sensitivity, specificity, and accuracy were 92%, 92%, and 92%, respectively, indicating 
that this 8-gene panel is comparable in prediction performance to the 10-gene panel (Fig 
3, Fig. 4). 
Then, we validated the methylation levels of these 8 genes against the training 
sample set quantitatively by pyrosequencing. The methylation levels by pyrosequencing 
were confirmed to be similar to those by Infinium, and the ROC analysis resulted in an 
AUC value of 0.94, and sensitivity, specificity, and accuracy of 88%, 83%, and 86%, 
respectively (Fig 4). 
 
Validation of the prediction performance 
We next performed pyrosequencing to detect the methylation status of the 8 
markers using 35 additional samples, which were independent of the training set. We also 
analyzed the correlation between methylation status and irradiation efficacy in the 
validation sample set (Fig. 5). The threshold methylation level was set at 28%, as 
indicated the best in the training sample set. The 35 validation samples were classified 
into 26 methylation(+) and 9 methylation(−) samples, and there was a significant 
correlation between the methylation(+) and responder groups (25/26 vs. 1/9, P = 3 × 10-
6). When we performed the ROC analysis for the 35 validation samples using the 8 marker 
genes, the AUC value reached 0.98, and the sensitivity, specificity, and accuracy were 
96%, 89%, and 94%, respectively (Fig. 5A). We further analyzed the prediction 
performances by adjusting methylation level using tumor cell content of each sample 
(Table S2 and Fig. S2). When adjusted, the accuracy for the efficacy prediction was 
slightly elevated. Adjustment using tumor cell content might improve the prediction 
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performance, although it could be too complicating in clinical settings and accuracy was 
as high as 94% without adjustment (Fig. 5A). 
Finally, we compared PFS between the methylation(+) and methylation(−) groups 
defined by the panel of 8 marker genes. We analyzed the 75 samples of both sets and 
found that the hazard ratio (HR) [95% confidence interval (CI)] of the methylation(+) 
group relative to the methylation(−) group was 0.08 (0.04, 0.19). PFS was significantly 
higher in the methylation(+) group (P = 2 × 10-9, log-rank test) (Fig. 5B). As HPV(+) 
OPSCC is known to correlate with better prognosis, HPV(+) samples in our cohort 
showed significantly favorable PFS than HPV(−) samples (P = 0.002) (Fig. S3). When 
the 46 HPV(+) and 29 HPV(−) samples were analyzed separately, the HR of the 
methylation(+) group remained significantly lower than that of the methylation(−) group 
in both HPV(+) patients (P = 2 × 10-5) and HPV(−) patients (P = 0.002) (Fig. 5B). The 
univariate analysis by Cox proportional hazard model showed some clinicopathological 
factors such as HPV status (P = 0.002), clinical stage ⅣA and ⅣB (P = 0.002, P = 0.007, 
respectively), and the panel marker status (≥ 1 marker with methylation level > 28%, P = 
5 × 10-13) as prognostic factors for PFS (Table 1). We then performed the multivariate 
analysis by Cox proportional hazard model, and the adjusted HRs for critical 
clinicopathological factors showed that the panel marker status (P = 1 × 10-5) was the 
only independent prognostic factor for favorable PFS (Table 1, Fig. S3). In addition, 
Kaplan-Meier curve of OS showed significantly preferable prognosis of the 
methylation(+) group than the methylation(−) group (HR 0.1 [95%CI: 0.03-0.4], P = 2 × 
10-5) (Fig. 5B, Fig S3). 
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Discussion 
 
In irradiation therapy against OPSCC, its invasiveness is considerable while 
ongoing stratification by HPV status does not necessarily predict which patients the 
irradiation would give the benefit. We therefore investigated the association between 
promoter DNA methylation and irradiation efficacy in this study, so that an appropriate 
stratification by establishing molecular classifier markers could help therapeutic 
optimization and de-escalation of OPSCC treatment. Methylation marker panel was 
successfully developed to act as an efficacy predictor with high accuracy. It is noteworthy 
that the utility of the established prediction marker panel was consistent regardless of 
HPV status. 
GO terms enriched in the 87 genes highly methylated in the responder samples 
included “cell adhesion” and “Ras signaling”. Notably, 3 of 8 marker genes (ROBO1, 
LBX1, SHISA6) were associated with these GO terms. Zhou et al. previously reported that 
ROBO1 expression is involved in liver metastasis and proliferation of colorectal 
carcinoma30. Another study reported that inhibition of ROBO1 signaling promotes 
metastatic invasion in pancreatic ductal adenocarcinoma31. Although the function of 
ROBO1 differs depending on the organ, this gene is involved in important mechanisms 
related to tumor progression. Previous experimental studies showed that LBX1 was 
involved in breast cancer metastasis32. Another marker gene, MYOD1, was reportedly 
indirectly involved in MMP-mediated cancer metastasis33. Although the functions of 
ROBO1, LBX1, and MYOD1 in head and neck cancer have not been reported, it has been 
suggested that some marker genes might be involved in cancer pathologies such as 
metastasis and proliferation in this type of cancer. Therefore, some of the marker genes 
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might perhaps be involved in metastasis or proliferation of cancer, leading to better 
prognosis after irradiation therapy, since irradiation therapy is presumably a curative 
treatment for the local area. 
HPV(+) OPSCC is distinct, with p53 degradation and retinoblastoma pathway 
inactivation, contributing to carcinogenesis34-36. Recently, HPV was described as an 
activator of DNA methyltransferase (DNMT), which might play a role in aberrant DNA 
methylation in HPV-associated cancers37. This may explain in part why HPV-positive 
samples correlated with the methylation(+) OPSCC (Fig. 3B). HPV(+) OPSCC is 
reportedly more sensitive to irradiation therapy than HPV(−) OPSCC8, 35, 38, 39. Therefore, 
we hypothesized that the significant correlation between the responder samples and the 
high methylation shown in this study might be due to HPV. However, the results from the 
PFS analysis for all samples showed a better PFS in methylation(+) samples than in 
methylation(−) samples regardless of HPV status. Additionally, the univariate analysis 
found that HPV status, marker status, and clinical stage were prognostic factors for PFS. 
Surprisingly, multivariate analysis evaluated the methylation status of the marker panel 
as the only independent prognostic factor for PFS. The established marker panel also 
distinguished the OS regardless of HPV status. These suggested clinical importance of 
aberrant methylation status as well as biological tumorigenic role.  
This study may have some limitations. First, the irradiation conducted in our cohort 
was all curative irradiation therapy, and the established marker panel exhibited high 
prediction performance. The performance against irradiation other than curative therapy, 
e.g. adjuvant or neo-adjuvant irradiation, however, is yet to be evaluated. Second, we 
defined the non-responder patients as those whose cancer relapsed within six months after 
receiving irradiation therapy, as previously defined in the clinical trials that enrolled 
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HNSCC patients with radio- or chemo-resistance40, 41. The marker panel established in 
this study could successfully predict patients with favorable outcome for long periods 
(Fig. 5B). If more favorable or unfavorable subgroups are desired to predict for precision 
medicine, it may be needed to screen larger cohort using various definitions of non-
responder patients such as relapsing within longer or shorter periods. Further study is 
necessary to elucidate why DNA methylation markers exhibit such a high prediction 
performance demonstrated in this study, as well as how high the performance could be 
improved. 
In summary, we established a panel of gene markers to predict irradiation efficacy 
against OPSCC based on methylation status. 
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Figure legends: 
 
Fig. 1 
Study participants and design. (A) Diagram of participant inclusion and exclusion 
criteria in the training sample set (n = 40). (B) A flowchart of the study. (C) Overview of 
the definition of therapeutic efficacy. The vertical axis represents total tumor volume, and 
the horizontal axis represents the time-lapse from the end of the irradiation period. Red 
and blue lines, non-responder and responder cases, respectively. Arrowhead, relapse 
including local or locoregional relapse and distant metastasis. 
 
Fig. 2 
Infinium 450K analysis of OPSCC. The patients underwent curative irradiation 
therapy/concurrent chemoradiotherapy (including cetuximab-based bioradiotherapy) as 
first-line treatment. Unsupervised two-way hierarchical clustering was performed based 
on Infinium 450K data, using 2,112 genes with β-values that highly deviated between the 
analyzed samples (SD > 0.11) (top left). The high methylated group were significantly 
associated with good response (P = 0.02). †, P < 0.05 (Fisher’s exact test). Closed box, 
HPV-L1(+), smoking(+) (Brinkman index ≥ 200), and responder for irradiation therapy; 
open box, HPV-L1(−), smoking(−) (Brinkman index < 200), and non-responder for 
irradiation therapy (bottom). Location of Infinium probes was shown at the center: closed 
bar, CpG island (CGI); grey bar, CGI shore; open bar, other region. Three gene clusters 
showing different methylation levels between High- and Low-methylation groups (right). 
*, significantly hypermethylated in the High-methylation group. The terms of 
significantly-enriched categories in the GO analysis are shown. High or H, High-
methylation group; Low or L, Low-methylation group; NR, non-responder; R, responder.  
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Fig. 3 
Extraction of prediction markers for irradiation response using 40 training samples. 
(A) Comparison of methylation status between responders and non-responders in the 
training sample set (n = 40). Genes with significantly different methylation status (P < 
0.01) were extracted (n = 92) (left). Location of Infinium probes was shown at the center: 
closed bar, CpG island (CGI); grey bar, CGI shore; open bar, other region. Distance from 
TSS was also shown: closed bar, 0 - 200 base pairs upstream from TSS; open bar, other 
region. The GO analysis identified 87 significantly-hypermethylated genes in the 
responder group, GO terms such as "cell adhesion" and "regulation of cell proliferation" 
were significantly enriched (right). Among the genes significantly methylated in the 
responder group, we extracted the most significant 10 genes as candidate efficacy 
prediction markers. (B) Efficacy prediction performance of irradiation therapy based on 
extracted marker candidates. The methylation(+) group was significantly associated with 
the responder (P = 7 × 10-7) and HPV status (P = 0.006). *, P < 0.01 (Fisher’s exact test). 
(C) A ROC curve was drawn using β-values and therapeutic efficacy of the training 
samples. The sensitivity, specificity, and accuracy were 92%, 93%, and 93%, respectively, 
where β-value = 0.28 maximized the accuracy of the efficacy prediction.  
 
Fig. 4 
Validation of promoter DNA methylation status by pyrosequencing. The methylation 
levels of candidate marker genes analyzed by Infinium for the 40 training samples are 
shown on the color scale (top left). Validation by quantitative methylation analysis was 
performed using pyrosequencing. Pyrosequencing primers for 8 of the 10 markers could 
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be generated (bottom left). ROC curves were drawn using Infinium and pyrosequencing 
data of the 8 markers (right). 
 
Fig. 5 
Validation of prediction performance using 35 validation samples. (A) The significant 
correlation between the marker panel status and the therapeutic efficacy with the high-
accuracy prediction performance was verified by pyrosequencing of the 8 markers in the 
validation sample set. (B) Kaplan-Meier curves of progression-free survival (PFS) and 
overall survival (OS). PFS and OS were analyzed using 75 OPSCC samples, showing a 
markedly favorable outcome in the methylation(+) group than the methylation(−) group. 
Even when HPV(+) and HPV(−) patients were analyzed separately, the methylation(+) 
group showed significantly better outcome, regardless of HPV status (See also Fig. S3). 
**, P < 0.01 (Fisher’s exact test); *, P < 0.05 (Fisher’s exact test); NR, non-responder; R, 
responder; M(+), the methylation(+) group; M(−), the methylation(−) group; HR, hazard 
ratio. 
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Supporting Materials and Methods 
Full information for Materials and Methods is described below. 
 
Clinical samples 
In this study, we analyzed 75 clinical OPSCC specimens (40 for the training set and 35 for the 
validation set). 
For the training sample set, we enrolled 57 untreated OPSCC patients who visited Chiba 
University Hospital from July 2015 to September 2017 for receiving curative 
irradiation/chemoradiotherapy/cetuximab-based bioradiotherapy. A total of 17 patients were excluded 
from this study because they were transferred to other hospitals, had undergone radical surgery before 
irradiation therapy, interrupted treatment due to adverse events, or withdrew before treatment. The 
specimens of the remaining 40 patients formed the training set (Fig. 1A). For the validation set, we 
enrolled 35 OPSCC patients who received irradiation therapy as first-line treatment at Chiba 
University Hospital (n = 30) from September 2017 to March 2019 (fresh frozen specimen) and from 
January 2008 to June 2010 (formalin-fixed paraffin-embedded specimen), or Hamamatsu University 
Hospital (n = 5) from December 2013 to November 2017. The enrolled patients were all Asian. We 
prepared H&E stained preparation for all the training and validation samples and checked the tumor 
content rate. Then samples with < 50% of tumor content rate were excluded from enrollment. 
We collected the following clinicopathological factors for all the patients enrolled in this study: 
age, gender, tumor site, HPV-L1 status, clinical stage (T, N, stage based on UICC 8th edition), 
Brinkman index of 200 as smoking behavior, irradiation dose, and combination chemotherapy (Table 
S1). The 40 specimens of the training set were collected during biopsies performed before treatment, 
immediately frozen in liquid nitrogen, and stored at −80°C. Regarding the 35 validation samples, 24 
were frozen specimens, and 11 were formalin-fixed paraffin-embedded (FFPE) specimens. 
All the participants were classified as either responders or non-responders. We defined 
responders as patients who reached complete remission (CR) status and maintained it for > 6 months 
after irradiation therapy, or those for whom we did not find viable cancer cells the specimen collected 
during rescue surgery after irradiation. We defined non-responders as patients who did not reach CR, 
those who had viable cancer cells in the specimen collected during rescue surgery after irradiation, or 
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those who temporarily achieved CR but relapsed locally or by distant metastasis within six months 
after irradiation (Fig. 1C). 
Two independent pathologists microscopically examined the tumor cell content on the frozen or 
FFPE clinical specimens. The specimens were dissected to enrich the tumor cells when necessary. We 
used 75 samples with > 50% of tumor cell content for subsequent molecular analyses. DNA was 
extracted using a QIA quick DNA mini-kit (Qiagen, Hilden, Germany) for frozen material and 
QIAamp DNA FFPE Tissue Kit (Qiagen) for FFPE material. The institutional review boards at Chiba 
University and Hamamatsu University approved the study protocol.  
 
Amplification of L1 DNA region in high risk HPV  
We evaluated HPV infection by amplifying a portion of the L1 region of high-risk HPV We 
evaluated HPV infection by amplifying a portion of the L1 region of high-risk HPV including HPV 
16, 18, 31, and 33 in the 40 training and 35 validation samples, using GP5 and GP6 primers (GP5: 5′-
TTTGT TACTG TGGTA GATAC-3′; GP6: 5′-GAAAA ATAAA CTGTA AATCA-3′) as previously 
reported25. Positive PCR amplification was designated as HPV-L1(+).  
 
Infinium assays 
The Infinium assay of the training sample set were previously performed and the data were 
registered at GEO [accession number GSE124633]. The Infinium HumanMethylation450 BeadChip 
(Illumina) contains approximately 485,577 individual CpG sites. The β-value, ranging from 0.00 to 
1.00, was measured by a methylated probe relative to the sum of the methylated and unmethylated 
probes. The CpG score for each probe was calculated based on previous reports26, 27. Before analyzing 
the Infinium data, we extracted the upstream probe nearest to the transcription start site (TSS) of each 
gene (excluding sex chromosome genes) (n = 15,212) among 485,577 probes designed on the human 
genome. Among 15,212 probes, 10,048 (66%) were located in CpG islands and 2,852 (19%) in CpG 
island shores, according to annotation by Illumina. Probes showing standard deviation (SD) > 0.11 
among the training samples (n = 2,112) were extracted and used for the unsupervised two-way 
hierarchical clustering analysis. 
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Gene Ontology (GO) analysis 
The GO enrichment analysis was conducted based on GO terms (biological process, cellular 
component, and molecular function) using the Gene Annotation and Analysis Resource at Metascape 
(http://metascape.org/gp/index.html#/main/step1). 
 
Pyrosequencing analysis 
The quantitative validation of methylation level in the 40 training and 35 validation samples 
was performed by pyrosequencing using the PyroMark Q96 (Qiagen) as previously reported27. 
Bisulfite conversion was performed using the Zymo EZ DNA Methylation Kit (Zymo Research, Irvine, 
CA) and 500 ng of genomic DNA for each sample. We amplified the promoter region covering the 
interested Infinium probe site and several surrounding CpG sites using bisulfite-treated DNA as a 
template. The amplification primers were designed by Pyro Q-CpG Software (Qiagen) and are shown 
in Supporting information (Table S2). We calculated the average methylation value at the analyzed 
CpG sites as the representative methylation level of the gene. We prepared methylation control samples 
(0%, 25%, 50%, 75%, and 100%) as described previously28, 29, and analyzed them to confirm the 
quantification quality of the pyrosequencing assays (Fig. S1). 
 
Statistical analysis 
The association between clinicopathological factors and HPV-L1 status or DNA methylation 
was analyzed using Fisher’s exact test, χ2 test, and Student’s t-test. Unsupervised two-way hierarchical 
clustering was performed using Cluster 3.0 using the C Clustering Library version 1.59 software. We 
conducted the receiver operating characteristic (ROC) analysis in the training and validation sample 
sets to calculate the area under the curve (AUC) value. Progression-free survival (PFS) was measured 
from the completion date of irradiation therapy until the date of any relapse (local, locoregional, or 
distant metastasis) or death. OS was measured from the date of biopsy until the date of death. We 
estimated the PFS and OS distribution by the Kaplan-Meier method, and the difference between 
groups was determined by a log-rank test using R software (www.r-project.org/). The univariate and 
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multivariate analyses were performed using the Cox proportional hazard model for PFS. P < 0.05 was 
considered statistically significant. 
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Supporting Table S1. Patients’ characteristics 
 All cases Responder Non-responder P-value 
Variable (n = 75) (n = 52) (n = 23)  
Gender (male), n (%) 60 (80) 41 (79) 19 (83) 1.0  
Age (> 60), n (%) 59 (79) 42 (81) 17 (74) 0.5 
Tumor site, n (%)     
Tonsils 56 (75) 41 (79) 15 (65) 0.3 
Base of tongue 11 (15) 9 (17) 2 (9) 0.5 
Soft palate 7 (9) 2 (4)  5 (22) 0.03* 
Posterior wall 1 (1) 0 1 (4) 0.3 
HPV(+), n (%) 46 (61) 38 (73)  8 (35) 0.002* 
Clinical T stage (T3-4), n (%) 28 (37) 18 (35) 10 (43) 0.6 
Clinical N stage, n (%)     
N0 19 (25) 17 (33) 2 (9) 0.04* 
N1 4 (5) 3 (6) 1 (4) 1 
N2 47 (63) 30 (58) 17 (74) 0.2 
N3 5 (7) 2 (4)  3 (13) 0.2 
Lymph node metastasis, n (%) 56 (75) 35 (67) 21 (91) 0.04* 
Clinical stage, n (%)     
I 14 (19) 12 (23) 2 (9) 0.2 
II 27 (36) 23 (44)  4 (17) 0.04* 
III 17 (23) 11 (21)  4 (17) 1.0  
IVA 17 (23)  6 (12) 11 (48) 0.002* 
IVB 2 (3) 0 2 (9) 0.09 
Smoking (BI > 200), n (%)     
BI ≥ 200 59 (79) 42 (81) 17 (74) 0.5 
BI < 200 13 (17)  8 (15)  5 (22) 0.5 
N/A 3 (4) 2 (4) 1 (4) 1 
Irradiation dose (> 60Gy), n (%) 66 (88) 47 (90) 19 (83)  
Combination chemotherapy, n (%)     
none 11 (15)  8 (15)  3 (13) 1 
CDDP 38 (51) 31 (60)  7 (30) 0.03* 
Cetuximab 15 (20)  9 (17)  6 (26) 0.5 
CDDP + 5-Fluorouracil 11 (15) 4 (8)  7 (30) 0.03* 
HPV, human papillomavirus; BI, Brinkman index; CDDP, cisplatin; *, P < 0.05. 
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Supporting Table S2. Distribution of the tumor cell content in each sample set 
 All cases Training set Validation set 
# of cases 75 40 35 
Tumor cell content    
50% 29 20 9 
60% 19 8 11 
70% 7 4 3 
80% 14 2 12 
90% 1 1 0 
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Supporting Table S3. Primers for pyrosequencing 
Gene strand Primer types Primer sequence 
Anneal 
(°C) 
product 
(bp) 
ROBO1 top Fwd GGAAAAATTTAATTTTTTTTTAGTAGAGAA 50.3 93 
  Rev* ATTTATATACAATACCTTCTACTCT   
  Seq AATTTTTTTTTAGTAGAGAATT   
ULK4P3 top Fwd GGTGAGGGGAAGATGTTTATG 56 69 
  Rev* CTCCTAAAAAATAAAAACCAATAACTTC   
  Seq GGGGAAGATGTTTATGT   
MYOD1 top Fwd ATTGGTTTAGGATTTTTTTTTTTTTAG 56 113 
  Rev* AACTTCCTCACCCCTAAC   
  Seq AGTTGTTAGTTTGGGTT   
LBX1 top Fwd* GTTGTTGGGGTTTTTAGTAATT 56 98 
  Rev ACCACCTAACACCTTTAAATAAC   
  Seq AAATTAACCAAACTAAAACC   
CACNA1A top Fwd GAGGGGGGAGGGGAGAGA 53 66 
  Rev* ACTAAAAATTACCTAAATTCCTTCCT   
  Seq GAGGGGAGAGAGAAG   
IRX4 top Fwd TTGGGAGGGAGAAGTAGGAGAG 56 87 
  Rev* ACCACCCCTACTCACTTTATTACCC   
  Seq GGGAGAAGTAGGAGAGT   
DPYSL3 top Fwd* GTTAGAGGAGGTAGTGTTGTTT 56 95 
  Rev CTACTCTAAACCCCTACTCC   
  Seq AACTCCCTAAAAACAAACAAAAAT   
ELAVL2 top Fwd AGTTTAAAAAGAAGGAGAGATTATTT 53 76 
  Rev* CCTTAATTTATTTTTCTTACCCCTTTTT   
  Seq AAAAGAAGGAGAGATTATTTTTTTA   
* Primers with 5ʹ-biotin tag.  
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Supporting Fig. S1. 
Quantitation of pyrosequencing assay. The representative result of pyrosequencing using 
methylation control samples for quantitating the promoter DNA methylation of LBX1. (A) The 
target sequence of sequence primer (Supporting Table S2) for LBX1. There were four CpG sites 
in the target sequence of LBX1. R in the target sequence represents G or A. CpG#3 (red) was the 
target site of the Infinium probe. (B) Quantitation result using methylation control samples. The 
percentages of methylation were shown on the top of each CpG site. (C) The correlation 
coefficient (R2) was calculated at the average of each CpG site to confirm that R2 >0.98. 
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Supporting Fig. S2. 
The adjusted prediction performances. The heatmaps and ROC curves were generated using the 
training and validation sample sets, based on the raw pyrosequencing data and the data adjusted 
by tumor cell content. The accuracy for the efficacy prediction was slightly elevated (from 86% 
to 90% for the training set, and from 94% to 97% for the validation set).  
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Supporting Fig. S3. 
The Kaplan-Meier curves of the subgroup analysis for PFS and OS. The comparison of PFS and 
OS between HPV(+) and HPV(−) OPSCC. The HPV(+) OPSCC showed significantly better PFS 
and OS than the HPV(−) OPSCC [HR 0.3 (95%CI, 0.2-0.7), P = 0.002 and HR 0.3 (95%CI, 0.1-
0.9), P = 0.03, respectively] (left top and bottom). The Kaplan-Meier curve of 4 subgroups divided 
by the HPV and marker panel status for PFS and OS. The marker panel stratified the PFS and OS 
of all 75 samples into two groups regardless of HPV status (P = 6 × 10-11 and P = 3 × 10-4, 
respectively) (right top and bottom). The samples with no event until 60 months were censored at 
60 months. Solid line, HPV(+) group; dotted line, HPV(−) group; blue line, the methylation(+) 
group; red line, the methylation(−) group; M(+), the methylation(+) group; M(−), the 
methylation(−) group. 
 
  
Fig. S3. 
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